A Prospective CSFV-PCV2 Bivalent Vaccine Effectively Protects Against Classical Swine Fever Virus and Porcine Circovirus Type 2 Dual Challenge and Prevents Horizontal Transmission

Overview

Journal Vet Res

Publisher Biomed Central

Specialty Veterinary Medicine

Date 2023 Jul 11

PMID 37434231

Authors

Jing-Yuan Chen

Chi-Ming Wu

Min-Yuan Chia

Chienjin Huang

Maw-Sheng Chien

Affiliations

Soon will be listed here.

Abstract

Classical swine fever virus (CSFV) infection leading to CSF outbreaks is among the most devastating swine diseases in the pig industry. Porcine circovirus type 2 (PCV2) infection, resulting in porcine circovirus-associated disease (PCVAD), is also a highly contagious disease affecting pig health worldwide. To prevent and control disease occurrence, multiple-vaccine immunization is necessary in contaminated areas or countries. In this study, a novel CSFV-PCV2 bivalent vaccine was constructed and demonstrated to be capable of eliciting humoral and cellular immune responses against CSFV and PCV2, respectively. Moreover, a CSFV-PCV2 dual-challenge trial was conducted on specific-pathogen-free (SPF) pigs to evaluate vaccine efficacy. All of the vaccinated pigs survived and showed no clinical signs of infection throughout the experimental period. In contrast, placebo-vaccinated pigs exhibited severe clinical signs of infection and steeply increased viremia levels of CSFV and PCV2 after virus challenge. Additionally, neither clinical signs nor viral detections were noted in the sentinel pigs when cohabitated with vaccinated-challenged pigs at three days post-inoculation of CSFV, indicating that the CSFV-PCV2 bivalent vaccine completely prevents horizontal transmission of CSFV. Furthermore, conventional pigs were utilized to evaluate the application of the CSFV-PCV2 bivalent vaccine in field farms. An adequate CSFV antibody response and a significant decrease in PCV2 viral load in the peripheral lymph nodes were observed in immunized conventional pigs, suggesting its potential for clinical application. Overall, this study demonstrated that the CSFV-PCV2 bivalent vaccine effectively elicited protective immune responses and the ability to prevent horizontal transmission, which could be a prospective strategy for controlling both CSF and PCVAD in commercial herds.

Citing Articles

Newcastle Disease Virus Expressing Cap Gene of Porcine Circovirus Type 2 Confers Protection in Mice and Induced Long-Lasting Neutralizing Antibodies in Pigs.

Dey S, Murugasamy R, Buragohain L, Dsilva A, Sarma J, Bharali A Vaccines (Basel). 2024; 12(11).

PMID: 39591187 PMC: 11599103. DOI: 10.3390/vaccines12111285.

Development of a Ferritin-Based Nanoparticle Vaccine against Classical Swine Fever.

Song Y, Yuan Z, Ji J, Ruan Y, Li X, Wang L Vaccines (Basel). 2024; 12(8).

PMID: 39204071 PMC: 11360710. DOI: 10.3390/vaccines12080948.

Efficacy evaluation of a bivalent subunit vaccine against classical swine fever virus and porcine circovirus type 2.

Chen Y, Lee C, Wu C, Kao P, Chen T, Huang Y Sci Rep. 2024; 14(1):2997.

PMID: 38316873 PMC: 10844208. DOI: 10.1038/s41598-024-53624-w.

References

Richards K, Moritzky S, Shannon I, Fitzgerald T, Yang H, Branche A . Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans. NPJ Vaccines. 2020; 5:77. PMC: 7450042. DOI: 10.1038/s41541-020-00227-x. View

Walia R, Dardari R, Chaiyakul M, Czub M . Porcine circovirus-2 capsid protein induces cell death in PK15 cells. Virology. 2014; 468-470:126-132. DOI: 10.1016/j.virol.2014.07.051. View

Saade G, Deblanc C, Bougon J, Marois-Crehan C, Fablet C, Auray G . Coinfections and their molecular consequences in the porcine respiratory tract. Vet Res. 2020; 51(1):80. PMC: 7296899. DOI: 10.1186/s13567-020-00807-8. View

Ceppi M, de Bruin M, Seuberlich T, Balmelli C, Pascolo S, Ruggli N . Identification of classical swine fever virus protein E2 as a target for cytotoxic T cells by using mRNA-transfected antigen-presenting cells. J Gen Virol. 2005; 86(Pt 9):2525-2534. DOI: 10.1099/vir.0.80907-0. View

McIntosh K, Tumber A, Harding J, Krakowka S, Ellis J, Hill J . Development and validation of a SYBR green real-time PCR for the quantification of porcine circovirus type 2 in serum, buffy coat, feces, and multiple tissues. Vet Microbiol. 2008; 133(1-2):23-33. DOI: 10.1016/j.vetmic.2008.06.010. View

Koinig H, Talker S, Stadler M, Ladinig A, Graage R, Ritzmann M . PCV2 vaccination induces IFN-γ/TNF-α co-producing T cells with a potential role in protection. Vet Res. 2015; 46:20. PMC: 4348102. DOI: 10.1186/s13567-015-0157-4. View

Wu P, Chen T, Chi J, Chien M, Huang C . Efficient expression and purification of porcine circovirus type 2 virus-like particles in Escherichia coli. J Biotechnol. 2016; 220:78-85. DOI: 10.1016/j.jbiotec.2016.01.017. View

Chen J, Wu C, Liao C, Chen K, You C, Wang Y . The impact of porcine circovirus associated diseases on live attenuated classical swine fever vaccine in field farm applications. Vaccine. 2019; 37(43):6535-6542. DOI: 10.1016/j.vaccine.2019.08.039. View

Ferrari L, Borghetti P, De Angelis E, Martelli P . Memory T cell proliferative responses and IFN-γ productivity sustain long-lasting efficacy of a Cap-based PCV2 vaccine upon PCV2 natural infection and associated disease. Vet Res. 2014; 45:44. PMC: 3999888. DOI: 10.1186/1297-9716-45-44. View

10.

Dar P, Kalaivanan R, Sied N, Mamo B, Kishore S, Suryanarayana V . Montanide ISA™ 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle. Vaccine. 2013; 31(33):3327-32. DOI: 10.1016/j.vaccine.2013.05.078. View

11.

Vangroenweghe F . Good vaccination practice: it all starts with a good vaccine storage temperature. Porcine Health Manag. 2017; 3:24. PMC: 5713130. DOI: 10.1186/s40813-017-0071-4. View

12.

Ganges L, Crooke H, Bohorquez J, Postel A, Sakoda Y, Becher P . Classical swine fever virus: the past, present and future. Virus Res. 2020; 289:198151. DOI: 10.1016/j.virusres.2020.198151. View

13.

Ouyang T, Zhang X, Liu X, Ren L . Co-Infection of Swine with Porcine Circovirus Type 2 and Other Swine Viruses. Viruses. 2019; 11(2). PMC: 6410029. DOI: 10.3390/v11020185. View

14.

Hoffmann B, Beer M, Schelp C, Schirrmeier H, Depner K . Validation of a real-time RT-PCR assay for sensitive and specific detection of classical swine fever. J Virol Methods. 2005; 130(1-2):36-44. DOI: 10.1016/j.jviromet.2005.05.030. View

15.

Mutthi P, Theerawatanasirikul S, Roytrakul S, Paemanee A, Lekcharoensuk C, Hansoongnern P . Interferon gamma induces cellular protein alteration and increases replication of porcine circovirus type 2 in PK-15 cells. Arch Virol. 2018; 163(11):2947-2957. DOI: 10.1007/s00705-018-3944-1. View

16.

Suradhat S, Intrakamhaeng M, Damrongwatanapokin S . The correlation of virus-specific interferon-gamma production and protection against classical swine fever virus infection. Vet Immunol Immunopathol. 2001; 83(3-4):177-89. DOI: 10.1016/s0165-2427(01)00389-0. View

17.

Suradhat S, Damrongwatanapokin S, Thanawongnuwech R . Factors critical for successful vaccination against classical swine fever in endemic areas. Vet Microbiol. 2006; 119(1):1-9. DOI: 10.1016/j.vetmic.2006.10.003. View

18.

Zhao P, Wang C, Xia Y, Hu Y, Fang R, Zhao J . Seroprevalence Investigation of Classic Swine Fever Virus Before, During, and After African Swine Fever Virus Outbreak in Some Provinces of China from 2017 to 2021. Viral Immunol. 2022; 35(1):33-40. DOI: 10.1089/vim.2021.0109. View

19.

Perez L, Diaz de Arce H, Percedo M, Dominguez P, Frias M . First report of porcine circovirus type 2 infections in Cuba. Res Vet Sci. 2009; 88(3):528-30. DOI: 10.1016/j.rvsc.2009.11.014. View

20.

Segales J . Best practice and future challenges for vaccination against porcine circovirus type 2. Expert Rev Vaccines. 2014; 14(3):473-87. DOI: 10.1586/14760584.2015.983084. View